Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + ME...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Discov
Hlavní autoři: Erkes, Dan A., Cai, Weijia, Sanchez, Ileine M., Purwin, Timothy J., Rogers, Corey, Field, Conroy O., Berger, Adam C., Hartsough, Edward J., Rodeck, Ulrich, Alnemri, Emad S., Aplin, Andrew E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007378/
https://ncbi.nlm.nih.gov/pubmed/31796433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0672
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky